Primary Care and Outpatient Clinic

Encyclopedia of Measures

April 2023

Table of Contents

KY SOS Primary Care and Outpatient Clinic
Metric #1

Patients on long-term opioid therapy taking 50 MMEs (morphine milligram equivalents) or more per day.

Measure Type: Outcome

Description: The number of patients 18 years or older on long-term opioid therapy* who are taking 50 MMEs (morphine milligram equivalents) or more per day.

Numerator: Patients 18 years or older on long-term opioid therapy who are taking 50 MMEs (morphine milligram equivalents) or more per day.

Denominator: Patients 18 years or older on long-term opioid therapy seen during reporting month.

Measure Exclusions: Patients 18 years or older receiving pain management related to sickle cell disease, cancer-related pain treatment, palliative care, hospice care or end-of-life care.

Frequency of Reporting: Monthly

*Long-term opioid therapy will be defined as the following for KY SOS: Use of an opioid for 90 days or greater (3 consecutive months of opioid use).

https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm?s_cid=rr7103a1.htm

Schedule II opioids such as fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, opium, oxycodone, oxymorphone, tapentadol.

Baseline will be the first 3 months of the reporting period.

KY SOS Primary Care and Outpatient Clinic
Metric #2

Patients on long-term opioid therapy who are also on long-term benzodiazepine therapy.

Measure Type: Outcome

Description: The number of patients 18 years or older on long-term opioid therapy* who also received a prescription for long-term benzodiazepine therapy**.

Numerator: Patients 18 years or older on long-term opioid therapy who also received a prescription for long-term benzodiazepine therapy.

Denominator: Patients 18 years or older on long-term opioid therapy seen during reporting month.

Measure Exclusions: Patients 18 years or older receiving pain management related to sickle cell disease, cancer-related pain treatment, palliative care, hospice care or end-of-life care.

Frequency of Reporting: Monthly

***Long-term opioid therapy** will be defined as the following for KY SOS: Use of an opioid for 90 days or greater (3 consecutive months of opioid use).

https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm?s_cid=rr7103a1.htm_w

****Long-term benzodiazepine therapy** will be defined as the following for KY SOS: Use of a benzodiazepine for 90 days or greater (3 consecutive months of benzodiazepine use).

Schedule II opioids such as fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, opium, oxycodone, oxymorphone, tapentadol.

Benzodiazepines such as alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam, triazolam.

Baseline will be the first 3 months of the reporting period.

KY SOS Primary Care and Outpatient Clinic
Metric #3

Documentation of KASPER (PDMP) report for patients on long-term opioid therapy is present when opioid medication is prescribed.

Measure Type: Outcome

Description: The number of patients 18 years or older on long-term opioid therapy* with documentation that a KASPER (PDMP) report is checked at time of visit if opioid medication is prescribed.

Numerator: Patients 18 years or older on long-term opioid therapy with documentation that a KASPER (PDMP) report is checked at time of visit if opioid medication is prescribed.

Denominator: Patients 18 years or older on long-term opioid therapy seen during reporting month when opioid medication is prescribed.

Measure Exclusions: Patients 18 years or older receiving pain management related to sickle cell disease, cancer-related pain treatment, palliative care, hospice care or end-of-life care.

Frequency of Reporting: Monthly

*Long-term opioid therapy will be defined as the following for KY SOS: Use of an opioid for 90 days or greater (3 consecutive months of opioid use).

Schedule II opioids such as fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, opium, oxycodone, oxymorphone, tapentadol.

https://kbml.ky.gov/hb1/Documents/Summary%20of%20201%20KAR%209_260.pdf

Baseline will be the first 3 months of the reporting period.

KY SOS Primary Care and Outpatient Clinic
Metric #4

Documentation of Urine Drug Screen at least annually** for patients on long-term opioid therapy.

Measure Type: Outcome

Description: The number of patients 18 years or older on long-term opioid therapy* with documentation that a urine drug screen was performed at least annually (**with a 12 month lookback period).

Numerator: Patients 18 years or older with documentation that a urine drug screen was performed at least annually ** when seen by opioid prescribing provider (**with a 12 month lookback period).

Denominator: Patients 18 years or older on long-term opioid therapy seen during reporting month by opioid prescribing provider.

Measure Exclusions: Patients 18 years or older receiving pain management related to sickle cell disease, cancer-related pain treatment, palliative care, hospice care or end-of-life care.

Frequency of Reporting: Monthly

*Long-term opioid therapy will be defined as the following for KY SOS: Use of an opioid for 90 days or greater (3 consecutive months of opioid use).

**12 month lookback defined as during measurement reporting month and previous 11 months.

Schedule II opioids such as fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, opium, oxycodone, oxymorphone, tapentadol.

https://kbml.ky.gov/hb1/Pages/Considerations-For-Urine-Drug-Screening.aspx

Baseline will be the first 3 months of the reporting period.